FDA Accepted Takeda Application for Zasocitinib
The drug, an oral tyrosine kinase 2 inhibitor, is designed to treat moderate-to-severe plaque psoriasis.
Updated on Sept. 23, 2026 in Arthritis
Live Poll
Do you believe new oral treatments are a better approach to managing plaque psoriasis symptoms?
The FDA has accepted Takeda's New Drug Application for zasocitinib, a potential new oral therapy for plaque psoriasis. The agency also granted the application Priority Review status as part of the regulatory process.
Why it matters
The submission aims to address significant unmet medical needs for effective oral treatment options in patients suffering from psoriasis. Takeda is also pursuing regulatory approvals for the drug in Europe and other international markets.
Clinical study results involving approximately 3,000 patients showed that about 70% achieved clear or almost clear skin by week 16. Researchers observed skin clearance in some subjects as early as week 4 of the trial program.
The players
Takeda
This global research-driven pharmaceutical company is headquartered in Osaka, Japan, with major operations in Cambridge, Massachusetts.
FDA
The Food and Drug Administration is the United States federal agency responsible for regulating new drug applications.
European Medicines Agency
This agency is responsible for the scientific evaluation and monitoring of medicines for human use throughout the European Union.
The details
The application is supported by results from the pivotal LATITUDE PsO 3001, 3002, and 3003 studies. Beyond plaque psoriasis, Takeda is investigating the use of the inhibitor for psoriatic arthritis, Crohn's disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa.
Timeline
September 14, 2026: The FDA accepted the New Drug Application for zasocitinib.
First quarter of 2027: The target action date for the FDA decision on zasocitinib.
Health Landscape
The pursuit of this treatment highlights the ongoing evolution of oral tyrosine kinase inhibitors in dermatology. This submission follows the data benchmarks established by the LATITUDE PsO 3001 and 3002 pivotal trials.
If approved, zasocitinib would offer patients a new oral therapeutic option for managing plaque psoriasis. Patients should consult with their healthcare providers about emerging treatment availability and eligibility.
The takeaway
Takeda's move to secure regulatory approval reflects a shift toward expanding oral treatment options for chronic autoimmune conditions. Further study results for related indications like psoriatic arthritis and Crohn's disease remain key areas to monitor.
Further reading
Learn more about the latest developments in treatment options on the Arthritis section.
More information
View the clinical trial study details on the official government registry.
Source note: This article includes information reported by Drugs.
Live Poll
Do you believe new oral treatments are a better approach to managing plaque psoriasis symptoms?
